1	Dime	via immunaciate ulia. A colo noval diagnactic marker of mocoles infection				
1	Dimeric immunoglobulin A as a novel diagnostic marker of measies infection					
2	DIGA:	a new diagnostic marker for measies				
3						
4	Khayriyyah Mohd Hanafiah ^{1,3*} , Joanne Hiebert ² , Vanessa Zubach ² , Alberto					
5	Severini ^{2,4} , David A. Anderson ¹ , Heidi E. Drummer ^{1,5,6}					
6						
7	1.	Life Sciences, Macfarlane Burnet Institute, 85 Commercial Rd 3004				
8		Melbourne VIC Australia				
9	2.	Viral Exanthemata and STD Section, National Microbiology Laboratory, Public				
10		Health Agency of Canada, Winnipeg, Manitoba, Canada				
11	3	Department of Biology School of Arts and Sciences St John Fisher				
12	0.	University. Rochester. United States				
13	4.	Department of Medical Microbiology and Infectious Diseases, Faculty of				
14		Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada				
15	5	Department of Microbiology Monash University Australia				
16	6	Department of Microbiology and Immunology at the Peter Doberty Institute for				
17	0.	Infoction and Immunity, University of Molbourne, Australia				
1/		intection and infiniturity, oniversity of Melbourne, Australia.				
18						
19						
20						
21	*Corresponding Author:					

- 22 Khayriyyah Mohd Hanafiah smohdhanafiah@sjfc.edu
- 23

24 Abstract

25

26 Despite tremendous measles incidence reduction through universal vaccination, 27 elimination efforts rely on improved surveillance. Detection of anti-measles 28 immunoglobulin M (IgM) by ELISA is the standard laboratory diagnostic method. 29 However, true infection is rare and seroconversion following MMR vaccination also 30 generates IgM, which results in low positive predictive values of assays in elimination settings, thus necessitating confirmatory testing. Improved diagnostic tests for 31 32 measles infection are a World Health Organization (WHO) research priority. We 33 investigated whether dimeric immunoglobulin A (dlgA), the predominant antibody 34 produced in mucosal immunity, may be a marker of recent or acute measles infection. 35 We examined a serological panel of confirmed measles infection (anti-measles IgM positives, n=50, and non-measles infection with rubella (n=36), roseola (n=40), 36 37 chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever-rash illness of 38 unknown cause (n=37). Sera were examined on a Micrommune anti-measles IgM, 39 Euroimmun anti-measles virus lysate (VL) and nucleoprotein (NP) IgM kits. Assays were then modified to detect dlgA using an in-house protocol based on a recombinant 40 41 chimeric secretory component protein and anti-secretory component monoclonal 42 antibody. We observed significantly higher levels of anti-measles VL dlgA in measles samples than non-measles controls (p<0.001), and there was low correlation with IgM
(R²: 0.01, p value:0.487). Unlike IgM, dIgA reactive to measles NP was not detected
in most samples. Comparable diagnostic potential of anti-measles dIgA (AUC 0.920 0.945) to anti-measles IgM (AUC 0.986 – 0.995), suggests that dIgA may be a new
blood-based marker of acute measles, independent of IgM, which merits further
investigation and optimization.

49 50

51 Introduction

52

53 Measles morbillivirus is a single stranded, enveloped, negative sense RNA 54 paramyxovirus that is a significant cause of childhood morbidity and mortality (1). The 55 incidence of measles infection has declined due to high vaccine coverage. However, risks of sporadic community outbreaks have increased particularly in subpopulations 56 57 with lower childhood vaccine coverage, even in settings where measles has been 58 eliminated in the general population (2). Additionally, breakthrough infections from 59 primary and secondary vaccination failure due to non-response or waning immunity 60 have been reported (3-6). Sustained elimination efforts hinge on improved 61 surveillance (7). Thus, development, evaluation and scale up of improved diagnostics 62 including point-of-care rapid diagnostic tests to enable timely detection is a key WHO 63 research priority (1).

64 Currently, clinical symptoms of viral fever and rash, and history of exposure 65 followed by detection of anti-measles immunoglobulin M (IgM) by ELISA, is the 66 standard method of diagnosis. In outbreak investigations, detection of viral RNA 67 through reverse transcriptase polymerase chain reaction (RT-PCR) (8) or IgG avidity 68 assays (9) to confirm IgM results may be required. IgM "true" positivity may arise 69 following MMR vaccination (10) and commercial IgM ELISAs have varied accuracy 70 and low positive predictive values in elimination settings (11, 12).

71 Dimeric IgA is the predominant antibody class produced at mucosal surfaces. 72 and hence, an important part of the early immune response to infection that involve 73 the mucosa (13). In respiratory diseases such as COVID-19 and measles (14, 15), 74 studies typically measured secreted dlgA or secretory IgA (slgA) in saliva, nasal 75 washes or bronchoalveolar fluid. By contrast, IgM is the antibody class produced as 76 part of the primary humoral response to antigen (regardless of source) prior to class 77 switching and affinity maturation yielding IgG and IgA antibodies. Anti-measles IgM is 78 produced in response to both acute infection as well as MMR vaccination, and is 79 detectable in blood from 7 days up to 8 weeks post-infection and coincides with rash 80 onset.

81 We have previously shown that virus-specific dlgA is a promising blood-based 82 biomarker of acute infection in hepatitis A and hepatitis E infections (16). Longitudinal 83 observations in patients with hepatitis C and COVID-19 suggest that dlgA from natural 84 infection is transiently detectable in blood from 7 - 100 days (16, 17). In particular, data from a prospective study of dlgA response in COVID-19 suggest that dlgA from natural
infection is transiently detectable from 7 - 100 days (~14 weeks), and unlike IgG and
IgA responses which are sustained (18).

88 Considering that measles begins as a respiratory (mucosal) infection, we 89 hypothesised that anti-measles dlgA may be a serological marker of recent or acute 90 measles infection that is distinct and complementary or superior to the detection of 91 anti-measles IgM. While previous studies have relied on measuring slgA in secretions 92 to investigate mucosal responses, we previously established the use of a chimeric 93 secretory component protein in an indirect enzyme-linked immunoassay (ELISA) that 94 allowed selection of antigen-specific dimeric/polymeric IgA from total IgA in serum (16, 95 17), which otherwise is predominantly monomeric and not reflective of mucosal 96 immunity. Using this unique ELISA for dlgA detection, we show that i) anti-measles VL 97 dlgA, but not anti-measles NP is detectable in levels higher than IgM in confirmed 98 acute measles serum/plasma samples; ii) the anti-measles VL dlgA response is not 99 quantitatively correlated with anti-measles IgM response and; iii) the diagnostic potential of anti-measles dIgA (AUC 0.920 - 0.945) is comparable to anti-measles IgM 100 101 (AUC 0.986 – 0.995), albeit cross-reactivity observed in samples of patients with other 102 viral exanthematous infections resulted in lower assay specificity, which may be 103 improved with further assay optimization.

104

105 Materials and Methods

106

107 108 <u>Samples</u>

109

- 110 Preliminary studies were conducted on a well-described multi-timepoint commercial
- 111 panel of confirmed measles cases (n=9), from outbreaks in Czech Republic (Biomex
- 112 GmbH, Germany), a WHO proficiency test control panel (acute
- 113 rubella/parvovirus/dengue n=8; measles/rubella uninfected (confirmed IgM
- 114 negative)=19) kindly provided by Victorian Infectious Disease Reference Laboratory
- 115 (VIDRL) (Melbourne, Australia), and archived healthy donor (n=88) samples.
- 116
- 117 Results were validated by testing on a study panel comprising anonymized residual
- 118 sera referred to the National Microbiology Lab (NML) (Winnipeg, Canada) for
- 119 serological testing and included sera from laboratory confirmed measles cases,
- 120 (n=50), and sera with provisional diagnosis of rubella (n=36), roseola (n=40),
- 121 chikungunya/dengue/zika (n=41), parvovirus (n=35) and other fever and rash illness
- of unknown etiology (n=37). This complete panel was previously used to evaluate
- 123 the diagnostic accuracy of commercial assays for the detection of measles-specific
- 124 IgM antibodies (11).
- 125
- 126 <u>ELISA</u>

128 In-house measles VL antigen plate preparation

129

130 A batch of antigen measles Edmonston strain virus lysate (Zeptometrix, NY, USA) 131 were coated on F8 Maxisorp Nunc [™] (Thermo Scientific) microtiter plates following 132 an in-house sucrose stabilized ELISA plate coating protocol. Briefly, lysate was 133 diluted in bicarbonate pH 9.2 coating buffer at 2.5 μ g/mL, dispensed at 50 μ L/well, 134 incubated on a plate shaker at ambient temperature (AT) for 30 minutes and then 135 placed in a humidified lunchbox at 2-8°C for overnight incubation. Next day, the 136 coating solution was tipped out and 200 μ L/well of 5% skim milk in PBS was added to unwashed plates and incubated at AT for 2 hours to block the plates. A 5% 137 138 sucrose solution was then added to blocked plates and incubated for 10 mins at AT. 139 The sucrose solution was flicked out and allowed to air dry in a 37°C incubator for 3 140 hours, then placed in labelled aluminium foil pouches with desiccant, and stored at 2-141 8°C.

- 142
- 143 Commercial IgM kits and modification for dIgA detection
- 144

145 Commercial assays for the detection of IgM subclass antibodies specific to measles virus included Euroimmun measles IgM (cat # EI 2610-9601M, Medizinische 146

147 Labordianostika AG, Lübeck, Germany), Euroimmun measles NP (cat # El 2610-

148 9601-4M, Medizinische Labordianostika AG, Lübeck, Germany) and Microimmune

149 IqM (cat# MeVM010 Clin-Tech Ltd., Guildford, UK). IqM ELISAs were performed

- 150 according to manufacturers' protocols.
- 151

152 For detection of anti-measles dlgA, in-house lyophilized chimeric secretory 153 component (cSC) protein and anti-secretory component (anti-SC) antibody as 154 previously described (17, 18) were used in an indirect ELISA. Briefly, strips prepared 155 in-house and commercial pre-coated antigen strips (Euroimmun/Euroimmun NP kits) 156 were blocked with 1.5% bovine serum albumin for 1 hour at 37°C in a humidified 157 environment. Then, 4 μ g/mL of cSC was added to Euroimmun sample buffer and the serum/plasma was diluted at a ratio of 1:101 in the cSC-buffer mixture then 158 159 incubated for 10 minutes to allow for cross-absorption of IgG. To allow for cSC-dIgA complex to bind the antigen on the plate 100 μ L/well of cSC/sample mixture was 160 added to the antigen coated strips and incubated overnight at 2-8°C. A volume of 161 162 100 μ L/well of mouse anti-SC at 0.5 μ g/mL was added and the plate was incubated for 1 hr at 37°C. A volume of 100 µL/well of anti-mouse IgG horseradish peroxidise 163 164 (HRP) conjugate (cat# A16078, Invitrogen) at a 1:2000 dilution was added and 165 incubated for 1 hr at 37°C. Between each step, plates were washed with 450μ l of 166 0.05% PBS Tween-20 thrice with a 30 delay before aspirating using a BioTek 50TS 167 96-well plate waster. Finally, 100 μ L/well of Euroimmun tetramethylbenzidine (TMB) 168 substrate was added to the wells. In-house prepared strips were incubated for 10

171 acid. Optical densities were read with a Tecan sunrise microplate absorbance reader 172 immediately after the addition of the stop solution. The plates were slightly shaken 173 and read at a wavelength of 450nm with a reference wavelength of 650nm. Optical 174 density data were exported to a Microsoft Excel file for calculations and result 175 determinations. 176 177 178 Statistical analysis 179 180 Replicate optical density (OD) values were averaged, coefficient of variation (CV) was calculated to ensure acceptability (<15%), and S/Co values were calculated by 181 dividing average sample OD with average calibrator OD using Microsoft Excel. 182 183 Positive cut-off values for in-house assays were based on average OD or S/Co of 184 non-measles plus 2 standard deviations, and for commercial kits following 185 manufacturers' instructions. Kruskal-Wallis comparison of anti-measles dIgA and IgM 186 reactivity across multiple sample groups followed by pairwise Mann-Whitney U or 187 Welch's t-test post-hoc analysis. Pearson correlation of anti-measles dIgA and IgM 188 reactivity in measles sample group, area under curve (AUC) analysis comparing 189 measles and non-measles samples for dIgA and IgM were performed on GraphPad 190 Prism v.9.3 All statistical analyses were conducted two-tailed with alpha set at 0.05, 191 and a p value of <0.05 considered statistically significant, except for correlation 192 which was Bonferonni-adjusted to <0.01 for multiple comparisons. 193 194 Results 195 196 Anti-measles VL dlgA but not anti-measles NP detected in all patients with confirmed 197 acute infection

mins and Euroimmun strips were incubated for 15 mins in the dark. The reactions

were stopped with 100 μ L/well Euroimmun Stop solution containing 0.5M sulphuric

198

169

170

199 Confirmation of clinical symptoms and history of exposure to measles using a

200 laboratory-based anti-measles immunoglobulin M (IgM) ELISA is the standard

201 method of diagnosis. Several commercial assays of varying accuracy exist to detect

202 anti-measles IgM, including those against virus lysate and nucleoprotein (11). To

203 determine whether we could detect anti-measles dlgA, we employed a modified

indirect ELISA protocol using Euroimmun kits as well as in-house measles virus

205 lysate coated plates for detection of antigen-specific dlgA in plasma of individuals206 with acute measles infection and other viral exanthema conditions.

207

We first observed high anti-measles VL dlgA reactivity in the commercial panel of acute measles infection samples, which were significantly higher (Kruskal Wallis p <0.0001, Welch's t-test p<0.0001) than in healthy donors, acute 211 rubella/parvovirus/dengue infected and measles/rubella uninfected (IgM negative)

- samples, comparable to IgM reactivity as measured using commercial anti-measles
- VL kits from Euroimmun (Figure 1). In addition, we saw a significant difference in
- anti-measles VL dlgA versus IgM reactivity for individual samples (paired t-test p:0.026).
- 215 216

217 When the assay was repeated in a larger panel of acute measles samples, we 218 observed elevated levels of anti-measles VL dIgA compared to controls, albeit lower 219 than anti-measles VL dlgA reactivities measured in the earlier commercial panel or 220 using anti-measles IgM (Figure 2). While anti-measles VL dIgA reactivity was 221 observed in all measles samples on both in-house plates precoated with measles 222 virus (Edmonston strain) lysate (Zeptometrix, NY, USA) and the commercial measles 223 IgM precoated antigen plate (Euroimmun), the absorbance values were significantly 224 higher in assays run on the in-house antigen plates (Wilcoxon p <0.0001). Notably 225 however, only 18% (9/50) acute measles infection samples were above positive cutoff value for anti-measles NP dlgA, unlike anti-measles NP lgM, where 80% (40/50) 226 227 of the samples were considered positive for measles according to manufacturer cut-228 off. 229

- 230
- 230

a)

b)



C)

- 232
- 233
- Figure 1. Preliminary screening of Biomex vs VIDRL shows a) significantly elevated anti-measles VL dIgA S/Co or S/Cal ratios in measles samples compared to control
- samples, comparable to b) anti-measles VL IgM as determined using a Kruskal-
- 237 Wallis test followed by Welch's t-test post hoc; with c) individual acute measles
- 238 samples showing significantly different levels of anti-measles VL dlgA vs IgM on
- 239 paired t-test. Asterisks (****) denote statistical significance across all groups at
- 240 p<0.0001.

- 241
 242
 243
 244
 245
 246
 247
 248
- 249 250
- 251
- 252



Figure 2. Scatterplot of measles (open circles, n=50) and non-measles (open

255 diamonds, n=189) reactivities in OD units across assays. Asterisks (****) above line

 $256 \qquad \text{denotes statistical significance at } p < 0.0001, \text{ two-tailed as determined by Welch's t}$

- 257 test.
- 258

259260 Anti-measles VL dlgA and IgM responses are independent

261 262 While the high levels of anti-measles dlgA in acute samples confirms the presence of 263 this marker in measles infection, we wanted to determine whether the dlgA response was independent from the IgM response, and thus providing a different dimension of 264 diagnostic information. Hence, we performed a correlation analysis between the 265 reactivity of anti-measles dlgA versus anti-measles lgM in measles samples. 266 267 The correlation scatterplots (Figure 3) demonstrate that while overall anti-measles 268 VL dlgA reactivity is comparable to anti-measles VL IgM in patients with confirmed measles infection, individual patient responses are variable with most patients 269 having either higher anti-measles VL dlgA or anti-measles VL lgM. Correlation and 270 heatmap analysis suggests that anti-measles VL dlgA reactivity in patients is not 271 272 guantitatively correlated with anti-measles VL IgM. Despite much lower reactivity of 273 anti-measles NP dlgA among measles infected individuals, these levels appear to be significantly correlated with levels of anti-measles VL dlgA. 274 275

276



277

Figure 3. XY plots of antibody reactivity among acute measles samples (n=50)

shows low correlation between IgM and dIgA markers, but significant correlation

280 between anti-measles VL dIgA and anti-measles NP dIgA. Heat map (bottom left)

281 282	summarizes correlation of anti-measles IgM and dIgA evaluated in measles (n=50) samples based on Pearson r values, showing inverse relationship (shade of blue)
283	between anti-measles VL dlgA (on in-house plate) and Euroimmun anti-measles NP
284	IgN, albeit not reaching statistical significance. Asterisks denote statistical
285	(****)
287	
288	
289	Higher reactivity of anti-measles VL dIgA compared to IgM in measles patients, but
290	lower diagnostic potential due to cross-reactivity in non-measles controls
291	
292	Noting the challenge of comparing an in-house assay to optimized commercial
293	assays, we wanted to determine the diagnostic value of the dlgA assays at its
294	present iteration. Due to the lower dlgA reactivity observed against NP, we only
295	evaluated diagnostic potential of anti-measles VL dIgA against commercial IgM
296	assays.
297	
200	Although we observed high reactivity of anti-measles digA in acute measles on both
298	Although, we observed high reactivity of anti-measies digA in active measies of both
298 299	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using
298 299 300	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under
298 299 300 301	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The
298 299 300 301 302	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC
298 299 300 301 302 303	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the in-
298 299 300 301 302 303 304	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower
298 299 300 301 302 303 304 305	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false
298 299 300 301 302 303 304 305 306	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was
298 299 300 301 302 303 304 305 306 307	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL IgM having the
298 299 300 301 302 303 304 305 306 307 308	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the in-house plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL IgM having the highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP
298 299 300 301 302 303 304 305 306 307 308 309	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the in-house plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL IgM having the highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP IgM had the lowest AUC values among the commercial IgM assays (0.986, 95% CI:
298 299 300 301 302 303 304 305 306 307 308 309 310	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the in-house plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL lgM having the highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP IgM had the lowest AUC values among the commercial IgM assays (0.986, 95% CI: 0.973-0.999), overlapping the lower end of the confidence interval for anti-measles
298 299 300 301 302 303 304 305 306 307 308 309 310 311	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL lgM having the highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP IgM had the lowest AUC values among the commercial IgM assays (0.986, 95% CI: 0.973-0.999), overlapping the lower end of the confidence interval for anti-measles VL dlgA assay on Euroimmun VL plates (Table 1).
298 299 300 301 302 303 304 305 306 307 308 309 310 311 312	in-house VL and Euroimmun VL plates, comparison of diagnostic potential using receiver-operator curves (ROC) shows that the current dlgA assays under development have yet to reach accuracy comparable to the commercial assays. The anti-measles VL dlgA assay on the Euroimmun VL plates recorded a higher AUC (0.948, 95% CI: 0.917-0.980) value compared to the assay performed using the inhouse plates (AUC: 0.920, 95% CI: 0.882-0.959), albeit the former recorded lower ODs. This is likely due to the high cross-reactivity in a small proportion of false positive non-measles samples. The AUC value for anti-measles VL dlgA was significantly inferior to its IgM counterparts, with anti-measles VL IgM having the highest AUC at 0.995 and 100% sensitivity at 95% specificity. The anti-measles NP IgM had the lowest AUC values among the commercial IgM assays (0.986, 95% CI: 0.973-0.999), overlapping the lower end of the confidence interval for anti-measles VL dlgA assay on Euroimmun VL plates (Table 1).

Table 1. Area under receiver-operator curves (AUC) values and sensitivity of assays*

Assay	AUC (95% CI)	Sensitivity at ~95% specificity (95% CI)	Specificity at ~95% sensitivity (95% CI)
Anti-measles VL dlgA	0.920	58%	71%
(in-house)	(0.882 – 0.959)	(44 – 71%)	(65 – 77%)
Anti-measles VL dlgA	0.948	76%	69%
(Euroimmun)	(0.917 – 0.980)	(63 – 86%)	(62 – 75%)

Anti-measles VL IgM	0.995	100%	96%
(Euroimmun)	(0.990 – 1.000)	(93 – 98%)	(93 – 98%)
Anti-measles NP IgM	0.986	96%	96%
(Euroimmun)	(0.973 – 0.999)	(87 – 99%)	(93 – 98%)
Anti-measles IgM	0.993	98%	93%
(Microimmune)	(0.984 – 1.000)	(90 – 100%)	(69 – 100%)

*Note: Anti-measles VL dlgA were performed using in-house protocol on Euroimmun
 precoated antigen plates. Anti-measles IgM assays were performed according to

319 manufacturer's protocol. AUC values were analysed using OD units with the

- 320 Wilson/Brown method for determining confidence interval on GraphPad Prism v9.3.
- 321
- 322
- 323
- 324

325 **Discussion**

326

327 Rapid and accurate diagnostic tests are crucial tools contributing towards measles 328 elimination (1). While standard IgM-based serological tests exist to confirm measles 329 infection, low positive predictive values in low prevalence settings necessitates 330 discovery of alternative diagnostic markers (11, 12). A key challenge to further 331 biomarker discovery and diagnostic development is the fact that measles has been 332 eliminated in many parts of the world. Even in many countries where elimination 333 status is compromised, there is extremely low prevalence of measles except during 334 outbreaks. For example, in elimination settings such as Australia, 289 cases were 335 reported in 2019 (19), which makes it is challenging to obtain sufficient numbers of 336 true positive samples.

337

338 Nevertheless, a key strength of this study is the relatively large sample size of true 339 positives (n=50) that were evaluated, following their collection from laboratory 340 confirmed cases associated with measles outbreaks in Canada (11). Furthermore, 341 we included samples from patients with provisional diagnosis of several different viral 342 exanthematous conditions that are known to be sources of cross-reactivity such as 343 rubella and roseola (20). With access to these samples, we aimed to determine the 344 diagnostic potential of anti-measles dlgA, an important but under investigated 345 component of antibody response to many mucosal infections such as measles.

- 346
- 347 Using an in-house indirect ELISA protocol for dIgA detection (18) on in-house pre-
- 348 coated VL antigen plates and commercial plates, we observed the presence of anti-
- 349 measles VL dIgA in levels as comparably high as IgM in two independent panels of
- 350 confirmed acute measles serum/plasma samples (Figure 1, 2). Although the
- 351 distribution of anti-measles VL dIgA in measles samples was significantly higher than
- 352 non-measles controls on both in-house pre-coated antigen plates and Euroimmun

353 pre-coated antigen plates, the reactivity of measles samples in the latter was much

- lower. While being significantly higher in measles compared to non-measles
- 355 controls, we did not observe much, if any dIgA reactivity against measles NP antigen
- in a majority of the measles samples (Figure 2). Additionally, while correlation and
- 357 heatmap analysis demonstrated that the anti-measles VL dlgA response has low
- correlation and thus is independent from anti-measles IgM (Figure 3), the diagnostic
 potential of anti-measles dIgA as determined using AUC did not outperform the
- potential of anti-measles dIgA as determined using AUC did not outperform the
 commercial anti-measles VL and NP IgM assays due to a small number of high false
- 361 positives observed in samples of patients with other viral exanthematous infections
- 362 (Figure 1, Table 1).
- 363

364 These differences in dlgA reactivity among measles-infected subjects can be

- 365 explained by three underlying possibilities: 1) variability in antigen preparation
- 366 between commercial and in-house VL ELISA plates, 2) saturation or competition of
- 367 binding sites in NP by IgM, and 3) dIgA is made as part of early transitory response
- against specific antigens in lysate, rather than against NP.
- 369
- 370 Given that immobilization on the solid phase is a key source of assay variability,
- 371 especially for crude lysate preparations, it is likely that the lysate used to prepare in-
- house plates differed significantly in composition of individual proteins and the
- amount used to coat plates compared to the VL used in the commercial plates from
- 374 Euroimmun and Micromimmune. Indeed, even within the same manufacturer, batch-
- 375 to-batch variation of antigen-coated plates has been recorded with significant
- differences in diagnostic performance observed (11). Since the plates from
- 377 Euroimmun were part of an ELISA kit to specifically detect IgM, it is possible that the
- 378 lysate preparation and kit components on the Euroimmun plates were optimized for
- 379 IgM binding, leading to a saturation of binding sites by IgM.
- 380
- We have seen from previous studies in the laboratory that the current dIgA assay requires longer incubation time for efficient antigen binding, in part due to the cSC
- 383 detection protein that selects for dIgA requiring a conformational change upon
- binding (21), especially when the antigen is immobilized on a solid phase. Thus, it is
- 385 possible that the reduced reactivity observed on the Euroimmun plates reflect
- 386 selective binding and consequent saturation of anti-VL IgM on antigens before any
- 387 anti-VL dlgA present could effectively bind, rather than absence of the latter.
- 388
- 389 Related to this, where we saw high dlgA reactivity against measles VL antigens, we
- 390 observed lower dIgA reactivity against the measles NP antigen. Similarly with the VL, 391 there is possibility that the IgM present at higher levels (as suggested by the ODs in
- Figure 2) is saturating binding sites and out-competing the dlgA antibodies. While it
- is more difficult to pursue for a crude antigen such as VL, a dlgA capture assay for
- 394 NP and modifications to the sample buffer to remove competing antibodies of other

classes could be explored, which we have shown previously in acute hepatitis E samples and COVID-19 samples to be an effective way to isolate dlgA responses against a purified antigen (16, 17). Furthermore, a capture assay is the preferred format for future translation to a lateral flow platform, which arguably is the ideal point-of-care test type for improved global measles detection and surveillance (7).

401 Besides potential binding site competition, which we could not rule out in this 402 investigation, we also hypothesize that the lack of dlgA reactivity to measles NP, 403 despite it being the most abundant protein in infected cells and its presence in high 404 quantities in VL (22), suggests that most dlgA recognition is towards surface 405 exposed antigens such as H & F present in the VL (23). This aligns with the idea that 406 dlgA is generated as part of early immune response as seen in COVID-19 (14), and thus less likely to recognize NP, which is enclosed within virus nucleocapsid and 407 only released upon lysis of infected cells (22, 23). We cannot yet explain why we 408 409 observed higher false positives in the dlgA assays from non-measles controls 410 representing infections with other viruses of exanthematous conditions included in 411 the control group, but this may be due to cross-reactivity to cellular proteins in the

- 412 crude VL protein preparations.
- 413

414 That said, the dlgA assay has been successfully used to demonstrate elevated 415 levels of anti-measles VL dIqA in measles serum/plasma samples compared to 416 various non-measles controls with an AUC of 0.948, and a corresponding 76% 417 sensitivity at 95% specificity. The development of purified antigens such as F & H 418 proteins, which remains commercially unavailable, will be critical to overcome the 419 limitations of relying on crude antigens such as the measles VL. With better purified 420 antigens, assay optimisation could be pursued to overcome background issues by 421 increasing signal from true positive samples, reduce non-specific binding, and 422 optimize the assay on capture formats, which arguably will increase sensitivity and 423 specificity of dlgA as a novel blood-based marker of measles. 424

424

425

426

427

428 Conclusion

429

430 Dimeric IgA in blood has now been observed in various viral infections (16, 17).

431 While the literature is rich with characterizations of mucosal immunity and IgA in

432 secretions and mucosal surfaces (24), there are significant gaps in understanding of

433 dlgA as a serological biomarker. We show that anti-measles VL dlgA is detectable in

- 434 high levels in serum/plasma of measles cases, and is likely to be part of an early
- 435 response to infection that is independent from IgM production. The diagnostic
- 436 potential of anti-measles VL dIgA may be enhanced with optimization of antigen

- 437 preparation to increase separation of measles samples from non-measles controls
- 438 and reducing competition from other antibody classes. Our novel approach to
- 439 measuring dIgA response in blood may enable further examination of dIgA
- responses to measles and uncover new aspects of mucosal immunity for this prioritydisease.
- 442
- 443
- 444

445 **Funding**

- The authors would like to acknowledge funding from the Victoria-Jiangsu TechnicalCooperation grant and we also gratefully acknowledge the contribution to this work
- 448 of the Victorian Operational Infrastructure Support Program (Australia) received by
- the Burnet Institute. This study was also supported by the operating funds of the
- 450 Viral Exanthemata and STD Section at the National Microbiology Laboratory,
- 451 Manitoba, Canada.
- 452
- 453

454 Acknowledgments

- The authors would like to thank Irene Boo, Rob Center, Zihui Wei and Peter
- 456 Newman of Burnet Institute, Vicki Stambos and Suellen Nicholson of VIDRL, Wayne
- 457 Dimech and Joe Vincini of the Australian NRL, Brian Cao of Boint Biotech and other
- 458 collaborating organizations for provision of samples and reagents for this study.
- 459

460 **References**

- 461 1. WHO. 2020. Measles and Rubella Strategic Framework 2021-2030. World
 462 Health Organization, Geneva.
- 463
 463
 464
 464
 465
 465
 466
 467
 468
 465
 468
 469
 469
 469
 460
 460
 460
 460
 461
 461
 461
 462
 463
 464
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
 465
- 466 3. Fappani C, Gori M, Canuti M, Terraneo M, Colzani D, Tanzi E, Amendola A,
 467 Bianchi S. 2022. Breakthrough Infections: A Challenge towards Measles
 468 Elimination? Microorganisms 10:1567.
- 469
 4. Bianchi FP, Mascipinto S, Stefanizzi P, De Nitto S, Germinario C, Tafuri S.
 470
 471
 471
 471
 471
 472
 473
 474
 474
 474
 474
 475
 475
 476
 476
 476
 477
 477
 478
 478
 479
 479
 470
 470
 470
 470
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 471
 <li
- 472 5. Sasaki H, Fukunaga T, Asano A, Suzuki Y, Nakanishi Y, Kondo J, Ishikawa H,
 473 Shibata N. 2019. A Survey of Vaccine-Induced Measles IgG Antibody Titer to
 474 Verify Temporal Changes in Response to Measles Vaccination in Young
 475 Adults. Vaccines 7:118.
- 476
 6. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, Audet S,
 477
 477
 478
 478
 478
 478
 479
 471
 479
 471
 470
 471
 472
 473
 473
 474
 474
 475
 475
 476
 476
 477
 478
 478
 478
 479
 478
 479
 479
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470
 470</
- 480 7. Gastañaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA,

- 481 Patel M. 2021. Measles in the 21st Century: Progress Toward Achieving and 482 Sustaining Elimination. J Infect Dis 224. 483 8. Cui A, Mao N, Wang H, Xu S, Zhu Z, Ji Y, Ren L, Gao L, Zhang Y, Xu W. 2018. Importance of real-time RT-PCR to supplement the laboratory diagnosis 484 485 in the measles elimination program in China. PLoS One 13:e0208161. 486 9. Mercader S, Garcia P, Bellini WJ. 2012. Measles Virus IgG Avidity Assay for 487 Use in Classification of Measles Vaccine Failure in Measles Elimination 488 Settings. Clin Vaccine Immunol 19. 489 10. Brown DW, Warrener L, Scobie HM, Donadel M, Waku-Kouomou D, Mulders 490 MN, Rota PA. 2020. Rapid diagnostic tests to address challenges for global 491 measles surveillance. Curr Opin Virol 41. Hiebert J, Zubach V, Charlton CL, Fenton J, Tipples GA, Fonseca K, Severini 492 11. 493 A. 2021. Evaluation of Diagnostic Accuracy of Eight Commercial Assays for 494 the Detection of Measles Virus-Specific IgM Antibodies. J Clin Microbiol 59. 495 12. Warrener L, Bwogi J, Andrews N, Samuel D, Kabaliisa T, Bukenya H, Brown 496 K, Roper MH, Featherstone DA, Brown D. 2018. Serum anti-tetanus and 497 measles antibody titres in Ugandan children aged 4 months to 6 years: 498 implications for vaccine programme. Epidemiol Infect 146. 499 13. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. 2020. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. Front 500 501 Immunol 11. 502 14. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah 503 J, Devilliers H, Ghillani P, Gunn C, Hockett R, Mudumba S, Guihot A, Luyt C-504 E, Mayaux J, Beurton A, Fourati S, Bruel T, Schwartz O, Lacorte J-M, Yssel H, Parizot C, Dorgham K, Charneau P, Amoura Z, Gorochov G. 2021. IgA 505 506 dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl 507 Med 13. 508 15. Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Muñoz A, Lagos R, 509 Levine MM, Pasetti MF. 2011. Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles 510 511 Vaccine. Clin Vaccine Immunol 18:355-361. Mohd Hanafiah K, Garcia ML, Barnes NC, Anderson DA. 2018. Detection of 512 16. virus-specific polymeric immunoglobulin A in acute hepatitis A, C, E virus 513 514 serum samples using novel chimeric secretory component. BMC Res Notes 515 11. 516 17. Drummer HE, Van H, Klock E, Zheng S, Wei Z, Boo I, Center RJ, Li F, Bhat P, Ffrench R, Lau JS, McMahon J, Laeyendecker O, Fernandez RE, Manabe YC, 517 518 Klein SL, Quinn TC, Anderson DA. 2021. Dimeric IgA is a specific biomarker of 519 recent SARS-CoV-2 infection. medRxiv. 520 Wei Z, Angrisano F, Eriksson EM, Mazhari R, Van H, Zheng S, Center RJ, 18. 521 McMahon J, Lau J, Kiernan-Walker N, Ruybal-Pesántez S, Mueller I, Robinson 522 LJ, Anderson DA, Drummer HE. 2023. Serological assays to measure dimeric IgA antibodies in SARS-CoV-2 infections. Immunol Cell Biol 523 524 https://doi.org/10.1111/imcb.12682. 525 Winkler NE, Dey A, Quinn HE, Pourmarzi D, Lambert S, McIntyre P, Beard F. 19. 526 2022. Australian vaccine preventable disease epidemiological review series: 527 measles, 2012-2019. Commun Dis Intell 46.
 - 528 20. Thomas H. 1999. Simultaneous IgM reactivity by EIA against more than one

- 529 virus in measles, parvovirus B19 and rubella infection. J Clin Virol 14:107–118.
- 530 21. Stadtmueller BM, Huey-Tubman KE, López CJ, Yang Z, Hubbell WL,
- 531Bjorkman PJ. 2016. The structure and dynamics of secretory component and532its interactions with polymeric immunoglobulins. Elife 5.
- 533 22. Šantak M, Matić Z. 2022. The Role of Nucleoprotein in Immunity to Human
 534 Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral
 535 Nucleocapsid. Viruses 14:521.
- Laine D, Trescol-Biémont M-C, Longhi S, Libeau G, Marie JC, Vidalain P-O,
 Azocar O, Diallo A, Canard B, Rabourdin-Combe C, Valentin H. 2003. Measles
 Virus (MV) Nucleoprotein Binds to a Novel Cell Surface Receptor Distinct from
 FcγRII via Its C-Terminal Domain: Role in MV-Induced Immunosuppression. J
 Virol 77:11332–11346.
- 54124.Li Y, Jin L, Chen T. 2020. The Effects of Secretory IgA in the Mucosal Immune542System. Biomed Res Int 2020:1–6.